- Home
- MDCX vs ANEB Comparison
MDCX vs ANEB Comparison
Compare MDCX & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- ANEB
- Stock Information
- Founded
- MDCX 2008
- ANEB 2020
- Country
- MDCX United States
- ANEB United States
- Employees
- MDCX N/A
- ANEB N/A
- Industry
- MDCX
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- ANEB Health Care
- Exchange
- MDCX Nasdaq
- ANEB Nasdaq
- Market Cap
- MDCX 50.8M
- ANEB 111.8M
- IPO Year
- MDCX N/A
- ANEB 2021
- Fundamental
- Price
- MDCX $2.37
- ANEB $2.74
- Analyst Decision
- MDCX Strong Buy
- ANEB Buy
- Analyst Count
- MDCX 2
- ANEB 2
- Target Price
- MDCX $23.50
- ANEB $8.00
- AVG Volume (30 Days)
- MDCX 353.6K
- ANEB 28.4K
- Earning Date
- MDCX 11-22-2025
- ANEB 11-12-2025
- Dividend Yield
- MDCX N/A
- ANEB N/A
- EPS Growth
- MDCX N/A
- ANEB N/A
- EPS
- MDCX N/A
- ANEB N/A
- Revenue
- MDCX N/A
- ANEB N/A
- Revenue This Year
- MDCX N/A
- ANEB N/A
- Revenue Next Year
- MDCX N/A
- ANEB N/A
- P/E Ratio
- MDCX N/A
- ANEB N/A
- Revenue Growth
- MDCX N/A
- ANEB N/A
- 52 Week Low
- MDCX $1.79
- ANEB $0.80
- 52 Week High
- MDCX $8.94
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- MDCX 48.65
- ANEB 63.78
- Support Level
- MDCX $2.33
- ANEB $2.50
- Resistance Level
- MDCX $2.68
- ANEB $2.85
- Average True Range (ATR)
- MDCX 0.20
- ANEB 0.15
- MACD
- MDCX -0.01
- ANEB 0.04
- Stochastic Oscillator
- MDCX 26.37
- ANEB 82.26
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.